Why the study?
Does venovenous ECMO therapy with prophylactic subcutaneous enoxaparin only prevent severe bleeding without increasing thrombotic circuit occlusion in critical care patients?
Population
61 consecutive critical care patients without former thrombotic events treated with venovenous ECMO therapy
Design
Cohort
Follow-up
Median 7 days (range 2-32) of ECMO therapy
Authors
Loading...
May support prophylactic enoxaparin in vv-ECMO; hypothesis-generating and should not yet change practice pending RCTs.
Does venovenous ECMO therapy with prophylactic subcutaneous enoxaparin only prevent severe bleeding without increasing thrombotic circuit occlusion in critical care patients?
Venovenous ECMO therapy with prophylactic subcutaneous anticoagulation only appears feasible, potentially decreasing severe bleeding events without increasing system exchanges within permitted runtimes.
Krueger et al. (2016) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: